Clinical pharmacology of CNS 1102 in volunteers.
The high affinity noncompetitive N-methyl-D-aspartate receptor antagonist CNS 1102 (aptiganel hydrochloride, Cambridge NeuroScience, Cambridge, MA.) is neuroprotective in preclinical models of stroke when administered as pretreatment or up to 60 minutes postischemia, and has potential for treatment of acute stroke or traumatic brain injury in man. A total of 55 healthy male subjects have participated in three separate studies to determine the clinical pharmacology of CNS 1102, 43 of whom have received CNS 1102 in doses of up to 100 micrograms/kg. Administration of CNS 1102 has been studied as a 15-minute intravenous infusion, as a 15-minute loading intravenous infusion followed by a 4-hour maintenance infusion, or as a fixed-dose intravenous bolus over 90 seconds. CNS 1102 in normal volunteers is well tolerated in total doses up to 32 micrograms/kg whether as a bolus injection, 15-minute infusion or 4-hour infusion. Central nervous system affects are evident within minutes of administration, implying rapid drug penetration. CNS 1102 has a large and variable volume of distribution (mean +/- standard deviation, 6.2 +/- 1.9 l/kg), variable clearance (115 +/- 77 l/h), and plasma half-life of approximately 4.5 hours. Adjustment of doses by subject weight does not improve variability of these parameters, and fixed doses may thus be administered. CNS 1102 causes dose-dependent elevation of blood pressure, accompanied by clinical evidence of vasoconstriction. Global cerebral blood flow is maintained, whilst middle cerebral artery flow velocity increases. Symptoms of light-headedness, disorientation and paresthesia progress through euphoria, disinhibition, and hallucinations to psychomotor retardation, paranoia and catatonia as total administered dose increases.
D000328:Adult; D000804:Angiotensin II / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects*; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D004562:Electrocardiography / Q000187:drug effects; D004837:Epinephrine / Q000097:blood; D018691:Excitatory Amino Acid Antagonists / Q000493:pharmacokinetics* / Q000494:pharmacology* / Q000633:toxicity; D006146:Guanidines / Q000493:pharmacokinetics* / Q000494:pharmacology* / Q000633:toxicity; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate; D018696:Neuroprotective Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000633:toxicity; D009638:Norepinephrine / Q000097:blood; D010919:Placebos; D011674:Pulse / Q000187:drug effects; D011930:Reaction Time / Q000187:drug effects*; D012083:Renin / Q000097:blood; D013997:Time Factors
D018691:Excitatory Amino Acid Antagonists; D006146:Guanidines; D018696:Neuroprotective Agents; D010919:Placebos; D000804:Angiotensin II; C079779:aptiganel; D012083:Renin; D009638:Norepinephrine; D004837:Epinephrine